RxSight, Inc. (NASDAQ:RXST) Q2 2023 Earnings Call Transcript

David Saxon : Got it. Maybe a follow-up for Shelly. Just on the operating expense guidance. I think it implies around 33% growth in the back half versus 20% growth we saw in the first half. So, what’s driving that? What investments are you making — anything there would be helpful.

Shelley Thunen : Thank you so much. Of course, I did mention the stock expenses as well as the audit fees associated with stock. You get most of that right at the end of the year. And also, for the back-end year, we add clinical applications personnel in pace with our LDD sales. We had a few account managers and other people as we need to expand our marketing — and of course, by the third and fourth quarter, you get that full impact of those additions as well during the year. And that’s what really drives the OpEx up as you exit the year.

David Saxon : Great. Thank you.

Operator: I’m showing no further questions at this time, and I would now like to turn the conference back to Ron Kurtz for closing remarks.

Ron Kurtz : Well, thank you all for your time and attention today. As always, we appreciate your interest in RxSight and look forward to updating you on our progress in future quarters. Goodbye.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.